Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Antineoplastics

Various toxicities, compassionate use and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Medinger M, et al. CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL. eJHaem 3 : 1009-1012, No. 3, Aug 2022. Available from: URL: https://onlinelibrary.wiley.com/journal/26886146 Medinger M, et al. CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL. eJHaem 3 : 1009-1012, No. 3, Aug 2022. Available from: URL: https://​onlinelibrary.​wiley.​com/​journal/​26886146
Metadaten
Titel
Antineoplastics
Various toxicities, compassionate use and lack of efficacy: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48991-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Heparin

Case report

Multiple drugs

Case report

Multiple drugs